Added to YB: 2026-06-18
Pitch date: 2026-06-16
ENGN [bullish]
enGene Therapeutics Inc.
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada.
Market Cap
$108.5M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
0.90
P/E
-0.76
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Show full summary:
enGene Therapeutics Inc. ($ENGN)
ENGN: Clinical-stage biotech post-80% drop on failed LEGEND bladder cancer trial (13% 12mo cancer-free vs peers). Trades ~56% discount to net cash ($3.39/sh). Activist BML at 9.95% pushing realization. CMO exit, 50% RIF signal wind-down. CEO sold Albireo to Ipsen. Optionality on bladder rinse/BLA H2'26.
Read full article (7 min)